The Sarcopenia drugs in development market research report provides comprehensive information on the therapeutics under development for Sarcopenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Sarcopenia. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Sarcopenia and features dormant and discontinued products.

GlobalData tracks 58 drugs in development for Sarcopenia by 46 companies/universities/institutes. The top development phase for Sarcopenia is preclinical with 26 drugs in that stage. The Sarcopenia pipeline has 53 drugs in development by companies and five by universities/ institutes. Some of the companies in the Sarcopenia pipeline products market are: KSbitugen, Aventi and Animuscure.

The key targets in the Sarcopenia pipeline products market include Androgen Receptor (Dihydrotestosterone Receptor or Nuclear Receptor Subfamily 3 Group C Member 4 or DHTR or NR3C4 or AR), F Box Only Protein 32 (Atrogin 1 or Muscle Atrophy F Box Protein or FBXO32), and Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1).

The key mechanisms of action in the Sarcopenia pipeline product include Androgen Receptor (Dihydrotestosterone Receptor or Nuclear Receptor Subfamily 3 Group C Member 4 or DHTR or NR3C4 or AR) Agonist with three drugs in Phase II. The Sarcopenia pipeline products include seven routes of administration with the top ROA being Oral and 13 key molecule types in the Sarcopenia pipeline products market including Small Molecule, and Recombinant Protein.

Sarcopenia overview

Sarcopenia is an aging-associated condition which is characterized by loss of muscle mass, strength, and function. Symptoms include weakness, loss of endurance, and poor balance. Causes of sarcopenia include a loss of nerve cells, low hormone levels, and a decline in the body’s ability to convert protein to energy. Treatment includes hormone replacement therapy (HRT), exercise, and dietary supplements.

For a complete picture of Sarcopenia’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.